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We previously reported a cohort of elderly pa-
tients with concurrent development of debilitating
prurigo nodularis, extreme and disabling pruritus
with or without eczematous dermatitis, and keratoa-
canthomas in the presence of actinic damage.1 This
report is a long-term follow through on patients who
were successfully transitioned from cyclosporine,
acitretin, and topical 5-fluorouracil to subcutane-
ously administered methotrexate. We believe that an
underlying dysregulation of both inflammatory and
cell growth pathways predisposes these individuals
to the development of both types of lesions.1 Three
of the patients have since been successfully treated
with systemic methotrexate and are described
below. We stated in our original report that no
patients had keratoacanthomas while on cyclo-
sporine and acitretin; however, in reviewing the
material for this follow-up report, keratoacanthomas
were noted in the patients’ files. These lesions were
existing lesions that did not clear after the initiation
of therapy and were deemed suspicious enough for
further evaluation. Herein we describe patients who
underwent transition from cyclosporine to metho-
trexate and experienced relief of their symptoms.
Traditional treatment options for keratoacanthomas
include standard excision,Mohsmicrographic surgery,
systemic retinoids, radiotherapy, curettage and
electrodessication, and intralesional 5-fluorouracil.2
In patients with a predisposition to the development
of pruritic nodules and multiple keratoacanthomas,
many of the aforementioned treatments are ineffective
or only elicit some clinical response, often with
relapse.1New York University School of Medicine.
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umc.org.Intralesional methotrexate is noted in the litera-
ture as an effective and well-tolerated treatment
for solitary keratoacanthomas.2-4 However, this
approach may not be practical in the case of multiple
keratoacanthomas, especially if it is believed that a
predisposition exists for the development of addi-
tional lesions, as is the case in our patients.1 Systemic
methotrexate, used for rheumatoid arthritis5 and
psoriasis,6 has also been reported as an effective
treatment for prurigo nodularis.7 Some literature
supports the use of parenteral methotrexate as a
method to ensure uniform and predictable bioavail-
ability, particularly in doses at and greater than
15 mg.8-12 We have also observed that accessibility
of injectable methotrexate is far more affordable than
the oral tablet form, and patients are less likely to
confuse their dosing regimens with the subcutane-
ous format.
To our knowledge, there are no reports on the use
of systemic methotrexate to treat keratoacanthomas.
Three distinct cases are described in this report.
METHODS
We reviewed all cases of keratoacanthomas asso-
ciated with prurigo nodularis that were treated with
methotrexate at the New York University Langone
Medical Center between January 2000 and April
2015. Inclusion criteria included keratoacanthomas,
prurigo nodularis, and treatment with methotrexate
along with folic acid supplementation. A keratoa-
canthoma was defined as any histologically
confirmed keratoacanthomas or squamous cell car-
cinoma that was clinically crateriform, nodular, or
dome shaped. The presence of prurigo nodularisJAAD Case Reports 2016;2:269-71.
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270 Bieber, Cohen, and Steinwas defined as histologically confirmed prurigo
nodules or a pruritic lesion in the setting of a
histologically confirmed hypersensitivity reaction.
Analysis of the subjects’ charts included age, sex,
ethnicity, reason for visit, relevant history, course of
disease, treatments and doses, length of treatment,
adverse events, reason for discontinuation, charac-
teristics of biopsies, and unidentified localized pho-
tographs. Itching severity was not gauged by the
Visual Analog Scale or other visual scoring system.
Patients related incapacitating itch that resulted in
interference with activities of daily living, and, in
every patient, deep excoriations were present in
affected surface areas. Improvement was determined
based on alleviation of these factors as mentioned in
patient charts. The study was approved by New York




A 78-year-old woman presented with biopsy-
proven eczematous dermatitis and prurigo nodularis
and a clinical picture consistent with eruptive kera-
toacanthomas. She was treated with prednisone,
topical corticosteroids, tacrolimus, and emollients
over the year and a half prior to her presentation, but
none were more than temporarily helpful. She was
started on cyclosporine and acitretin, which resulted
in marked decrease in erythema, scale and indura-
tion. After 6 weeks on cyclosporine and acitretin,
there was a marked reduction in all skin lesions with
2 prominently persistent keratotic papules that were
consistent with keratoacanthomas and squamous
cell carcinoma on biopsy results. Over the next
4 years, even when cyclosporine was held intermit-
tently and eventually discontinued, some smaller but
persistent lesions were found to be keratoacantho-
mas. Acitretin was later discontinued because of leg
cramps.
Nearly 4 years after her initial presentation, the
patient still had many excoriated nodules and
plaques on the trunk and extremities. Weekly
intramuscular injections of 12.5 mg were started,
and there was a noticeable decrease in scale, crust,
and induration after 3 weeks. The patient also used
a topical compound containing triamcinolone ace-
tonide and pramoxine/hydrocortisone throughout
the course of methotrexate and 5% 5-fluorouracil
nightly to individual lesions in a 2 months on,
1 month off regimen. Nine months into metho-
trexate treatment, the patient remains markedly
improved with a decrease in number of lesions
and induration of each lesion and no new
keratoacanthomas.Case 2
A 78-year-old woman presented with eczematous
dermatitis and prurigo nodularis in sun-exposed
areas for 8 months, having been unsuccessfully
treated with topical steroids, prednisone, and emol-
lients. The patient was started on cyclosporine and
showed some improvement. Six weeks later, her
eczematous dermatitis was well controlled, but
eruptive keratoacanthomas started to develop, and
cyclosporine was discontinued. She continued aci-
tretin for more than 3 years and was concurrently
treated with 8 months of mycophenolate mofetil and
levocetirizine, 8 months of oral tacrolimus, and
liquid nitrogen to individual lesions. These treat-
ments were somewhat efficacious in reducing the
extent of excoriation; however, an infiltrating squa-
mous cell carcinoma developed while on tacrolimus
and continued to worsen over the next year.
Four years after her original presentation without
marked improvement, she began 10 mg of weekly
oral methotrexate without the aforementioned ther-
apies. After 1 month there was substantial improve-
ment in erythema and excoriations, and the dosewas
increased to 15 mg weekly in the form of subcu-
taneous injections. There was further improvement
after an additional 10 weeks, but the patient reported
nausea and an incidence of diverticulitis, so the dose
was decreased to 12.5 mg/wk. Two weeks later,
methotrexate was discontinued entirely because of
nausea and loss of appetite. After 2 weeks off the
methotrexate, new areas of erythematous plaques
and excoriations developed, and the patient re-
quested to restart treatment. Later that month, how-
ever, the patient was hospitalized for an infection,
and the methotrexate was discontinued. New lesions
developed since stopping treatment, but she remains
off methotrexate for now because of these adverse
events.
Case 3
An 80-year-old woman with a history of squa-
mous cell carcinoma presented with eczematous
dermatitis and prurigo nodularis that was treated
with fexofenadine, emollients, and clobetasol with
limited success. Because of the development of
widespread erythema and keratotic plaques, the
patient began acitretin and cyclosporine. After
1 month on cyclosporine, an infiltrating squamous
cell carcinomawith features of keratoacanthomawas
biopsied, and the dose of cyclosporine was reduced.
After some initial improvement on the new dose, the
patient presented 4 months later with worsening
prurigo nodularis, eruptive keratoacanthomas, and
actinic keratoses. She continued cyclosporine and
acitretin for 10 months until discontinuing the
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that time, one basal cell carcinoma developed on the
forehead. While continuing cyclosporine, the patient
was concurrently treated with 2 months of narrow-
band ultraviolet B therapy, intralesional metho-
trexate, intralesional triamcinolone, and 8 months
of mycophenolate mofetil, all without efficacy.
More than 3 years after her initial presentation, the
patient still suffered from eruptive keratoacanthomas
and prurigo nodules. Cyclosporine and mycophe-
nolic acid were discontinued, and the patient began
weekly subcutaneous injections of 15 mg of metho-
trexate. The patient had decreased plaque thickness
and quantity and improved itch about 7 weeks into
treatment, and her dose was reduced to 10 mg/wk
after 15 months of treatment. She has intermittent
follicular eruptions controlled with bleach baths and
desonide cream but has otherwise been under good
control.
DISCUSSION
Compared with cyclosporine in this small series,
methotrexate seems to yield marked improvement
with less potential risk for new lesion development.
Cyclosporine reduces the activation of various cyto-
kines and suppresses both the cell-mediated and
humoral immune responses and interferes with
leukocyte recruitment.13,14 Despite these immuno-
suppressive and anti-inflammatory effects, new le-
sions developed infrequently, and more often prior
lesions failed to involute in our patients. This finding
may be explained by cyclosporine’s suppression of
the immune surveillance system and possible stim-
ulation of transforming growth factor beta.15 It has
been noted in the literature that cyclosporine is
associated specifically with an increased risk for
cutaneous squamous cell carcinoma.16
Methotrexate has a lesser carcinogenic effect
because of its antiproliferative properties.17 Low-
dose methotrexate is also found to have anti-
inflammatory properties, although the mechanism
is not well understood. Recent investigations suggest
that this finding is owing to blockade of certain
pathways leading to an increase in adenosine, which
has potent anti-inflammatory effects.18 Despite the
antiproliferative properties, increased risk of cuta-
neous squamous cell carcinoma is associated with
high-dose methotrexate therapy.19 However, this
finding does not seem significant in patients
receiving low-dose methotrexate, as used in our
series, and no such lesions developed during treat-
ment. The quandary of the intractably itchy patient,
unresponsive to standard topical therapies in the
setting of carcinomatosis poses a vexing clinical
scenario. Subcutaneous methotrexate in the absenceof absolute contraindications may provide relief of
the prurigo lesions while assuaging the pruritic
symptoms without increasing the development of
keratoacanthomas in these high-risk patients.
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